Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Jounce Therapeutics (JNCE) Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
-
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
-
Jounce Therapeutics (JNCE) and Redx Announce Recommended Business Combination
-
Redx and Jounce Announce Recommended Business Combination
-
Form SC 13G/A Jounce Therapeutics, Filed by: Cowen Financial Products LLC
-
Jounce Therapeutics to Present at Upcoming Investor Conferences
-
Form SC 13G Jounce Therapeutics, Filed by: Cowen Financial Products LLC
-
Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference
-
UPDATE: Cowen Upgrades Jounce Therapeutics (JNCE) to Outperform
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
-
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
-
Jounce Therapeutics (JNCE) Prices 5M Share Common Offering at $11.25/Sh
-
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
-
Jounce Therapeutics (JNCE) to Offer Common Stock
-
Jounce Therapeutics Announces Proposed Offering of Common Stock
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
-
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
-
Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
-
Cowen Downgrades Jounce Therapeutics (JNCE) to Market Perform
-
Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
-
Jounce Therapeutics (JNCE): Two New Catalysts - Cowen
-
Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
-
Cowen Starts Jounce Therapeutics (JNCE) at Outperform
-
Jounce Therapeutics (JNCE) IPO Opens up 13%
-
Jounce Therapeutics Files $75M IPO, Plans to List on NASDAQ Under the Symbol 'JNCE'

